Oral News and Research

RSS

Report illustrates safety and efficacy of transoral robotic surgery for supraglottic laryngectomy

Robotic surgery though the mouth is a safe and effective way to remove tumors of the throat and voice box, according to a study by head and neck cancer surgeons at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

27 Sep 2012

Dr. Reddy's introduces generic Singulair oral granules in the U.S.

Dr. Reddy's Laboratories announced today that it has launched Montelukast Sodium Oral Granules, a bioequivalent generic version of Singulair (montelukast sodium) oral granules in the US market on September, 26, 2012, following the approval by the United States Food & Drug Administration (USFDA) of Dr.Reddy's ANDA for Montelukast Sodium Oral Granules.

27 Sep 2012

Enrollment complete in Boehringer Ingelheim’s nintedanib phase III studies for IPF

Boehringer Ingelheim Pharmaceuticals, Inc. announced that clinical trial enrollment has completed for two phase III studies evaluating the safety and efficacy of nintedanib (BIBF 1120), an investigational compound, in patients with idiopathic pulmonary fibrosis (IPF), being studied at a twice-daily oral dose.

27 Sep 2012

Alitair receives U.S. patent allowance for ion exchange resin formulation of benzonatate

Alitair Pharmaceuticals, Inc., today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its ion exchange resin formulation of benzonatate.

27 Sep 2012

Short-course amphotericin is cost-effective for cryptococcal meningitis

The treatment of cryptococcal meningitis in resource-limited settings is most effective with a short 1-week course of amphotericin induction therapy coupled with high-dose fluconazole for at least 2 weeks, a Ugandan study suggests.

26 Sep 2012

HPV-positive oropharyngeal cancer patients have more rapid and robust radiation-therapy response

UC Davis cancer researchers have discovered significant differences in radiation-therapy response among patients with oropharyngeal cancer depending on whether they carry the human papillomavirus (HPV), a common sexually transmitted virus. The findings, published online today in The Laryngoscope Journal, could lead to more individualized radiation treatment regimens, which for many patients with HPV could be shorter and potentially less toxic.

26 Sep 2012

EPO grants patent to Aeterna Zentaris’ AEZS-130 for diagnosis of growth hormone deficiency

Aeterna Zentaris Inc. today announced that the European Patent Office has granted a patent for the use of the ghrelin agonist, AEZS-130, related to methods and kits for use in relation to the diagnosis of growth hormone deficiency in a human or animal subject.

25 Sep 2012

UH Case Medical Center offers per-oral endoscopic myotomy for achalasia

University Hospitals (UH) Case Medical Center is one of five institutions nationwide performing a novel scarless procedure that restores swallowing function in some patients with achalasia, a rare condition where the esophagus is unable to move food into the stomach.

25 Sep 2012

New KSU molecule may deliver drugs inside the body to treat diseases

Kansas State University researchers have discovered a molecule that may be capable of delivering drugs inside the body to treat diseases.

25 Sep 2012

Extended release exenatide outperforms twice daily regimen

Once-weekly extended-release exenatide is a more effective treatment than twice-daily exenatide at improving glucose control among Japanese individuals with diabetes, report researchers.

24 Sep 2012

Age at onset influences juvenile dermatomyositis course

Children diagnosed with juvenile dermatomyositis at age 3 years or earlier have milder symptoms than patients with later onset, research suggests.

24 Sep 2012

BG-12 effective for relapsing–remitting multiple sclerosis

Results of the CONFIRM and DEFINE studies suggest that dimethyl fumarate should be considered as an oral treatment for patients with relapsing–remitting multiple sclerosis.

24 Sep 2012

NanoViricides’ oral FluCide dramatically improves survival in animals with H3N2 influenza A

NanoViricides, Inc. reported today that its oral FluCide drug candidates demonstrated dramatically improved survival in animals administered a lethal dose of the H3N2 influenza A virus.

24 Sep 2012

$Encouraging results from CTI’s pacritinib phase 1 study on relapsed/refractory lymphoma$

Encouraging results from CTI’s pacritinib phase 1 study on relapsed/refractory lymphoma

Cell Therapeutics, Inc. announced today that the phase 1 study data of its highly selective oral JAK2 inhibitor pacritinib, or SB1518, showed encouraging anti-tumor activity and good tolerability in 34 patients with relapsed/refractory lymphoma.

24 Sep 2012

Many AF patients not receiving oral anticoagulant therapy despite rapid adoption of dabigatran

A novel blood thinner recently approved by the FDA, dabigatran (Pradaxa), has been rapidly adopted into clinical practice, yet thus far has had little impact on improving treatment rates for atrial fibrillation.

24 Sep 2012

Researchers discover reliable predictors of pain

Researchers from Mount Sinai School of Medicine have identified reliable predictors of pain by surveying patients throughout their hospital stays about the severity of their pain and their levels of satisfaction with how their pain was managed by hospital staff.

24 Sep 2012

ASTRO's Annual Meeting to be held in Boston from Oct. 28-31

ASTRO's Annual Meeting is the premier scientific meeting in radiation oncology and is expected to attract more than 11,000 attendees including oncologists from all disciplines, medical physicists, dosimetrists, radiation therapists, radiation oncology nurses and nurse practitioners, biologists, physician assistants, practice administrators, industry representatives and other health care professionals from around the world.

24 Sep 2012

Oral News and Research

Report illustrates safety and efficacy of transoral robotic surgery for supraglottic laryngectomy

Dr. Reddy's introduces generic Singulair oral granules in the U.S.

Enrollment complete in Boehringer Ingelheim’s nintedanib phase III studies for IPF

Alitair receives U.S. patent allowance for ion exchange resin formulation of benzonatate

Short-course amphotericin is cost-effective for cryptococcal meningitis

HPV-positive oropharyngeal cancer patients have more rapid and robust radiation-therapy response

EPO grants patent to Aeterna Zentaris’ AEZS-130 for diagnosis of growth hormone deficiency

UH Case Medical Center offers per-oral endoscopic myotomy for achalasia

New KSU molecule may deliver drugs inside the body to treat diseases

Extended release exenatide outperforms twice daily regimen

Age at onset influences juvenile dermatomyositis course

BG-12 effective for relapsing–remitting multiple sclerosis

NanoViricides’ oral FluCide dramatically improves survival in animals with H3N2 influenza A

Encouraging results from CTI’s pacritinib phase 1 study on relapsed/refractory lymphoma

Many AF patients not receiving oral anticoagulant therapy despite rapid adoption of dabigatran

Researchers discover reliable predictors of pain

ASTRO's Annual Meeting to be held in Boston from Oct. 28-31

Topical NSAIDs as effective as oral NSAIDs for knee, hand arthritis

Arthroplasty wound complications linked to oral anticoagulant use

ChromaDex announces findings from pTeroPure Phase 2/3 trial on high blood pressure

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News